EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer

Keyphrases

• First-line Therapy 100%
• Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC) 100%
• Phase II Trial 100%
• Epidermal Growth Factor Receptor Inhibitors 100%
• Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI) 100%
• Epidermal Growth Factor Receptor 66%
• Non-small Cell Lung Cancer (NSCLC) 66%
• Gefitinib 66%
• Erlotinib 66%
• Histology 33%
• Clinical Trials 33%
• Non-smokers 33%
• Metastatic Non-small Cell Lung Cancer 33%
• Tyrosine Kinase Inhibitor 33%
• Active Agent 33%
• Platinum-based Chemotherapy 33%
• Bronchioloalveolar Carcinoma 33%
• Never-smokers 33%
• Unselected Patients 33%
• Subset Analysis 33%
• Platinum Doublets 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Non Small Cell Lung Cancer 100%
• Epidermal Growth Factor Receptor Kinase Inhibitor 100%
• Epidermal Growth Factor Receptor 33%
• Gefitinib 33%
• Erlotinib 33%
• Clinical Trial 16%
• Chemotherapy 16%
• Lung Alveolus Cell Carcinoma 16%
• Protein Tyrosine Kinase Inhibitor 16%